Podcasts about Lung cancer

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities.

Humans have long been exposed to three main types of smoke: from early domestic fires, modern wildfires, and more recently, tobacco and fossil fuel pollution. All release tiny particles from partly burned plants, containing harmful chemicals like nitrogen oxides and carcinogens. These particles raise risks for lung cancer, dementia, and even childhood obesity. Studies show that air pollution can disrupt brain chemistry, increase Alzheimer's-related proteins, and activate stress-related genes (NFkB, Nrf2). A new drug (GSM-15606) shows promise in reducing brain damage from pollution in mice. People with the ApoE4 gene may be more vulnerable, while the ApoE3 gene, possibly evolved 200,000 years ago, may offer some protection. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40700]

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

Since that first interview, Richard has faced multiple cancer recurrences—including brain tumors and cancer in his remaining lung—and continues to rely on cannabis oil as a central part of his healing. In this episode, he talks candidly about living with cancer, navigating the challenges of legalization, dealing with skeptical doctors, and staying grounded with family, humour, and positivity.00:37 – Introduction to Richard Lusk and his original interview from 201601:17 – How Richard first discovered his lung cancer02:45 – Starting cannabis oil and watching tumors shrink03:45 – Leaving Washington to care for his mother in Kansas—cannabis access cut off04:30 – Cancer returns and spreads to his brain05:38 – Returning to Washington for treatment and cannabis access06:10 – Telling his oncologist about cannabis oil07:02 – Doctors say it's incurable—Richard disagrees07:53 – How he takes a gram of cannabis oil each day08:54 – Symptoms that led to brain tumor discovery09:39 – Years in construction and staying physically resilient10:28 – Emotional vs. physical challenges of illness11:40 – Thoughts on legal cannabis access across the U.S.12:57 – Adrenal gland cancer and additional surgeries13:44 – Belief in cannabis over conventional treatments16:07 – The role of cannabis in surviving cancer17:40 – Advice for people newly diagnosed with cancer18:41 – Staying positive and the importance of family20:52 – Choosing your own path despite family opposition21:12 – Current restrictions and chemo side effects22:48 – Gratitude for life and simple pleasures23:26 – A brain surgeon's 6.5 rating and Richard's humour24:38 – Final thoughts, hope for change, and sharing his story Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

In the third episode of our lung cancer miniseries, Jonathan Sackier is joined by Douglas E. Wood, Henry N. Harkins Professor and Chair of Surgery at the University of Washington. A global leader in thoracic oncology, Wood explores the critical role of lung cancer staging, the evolution of screening guidelines, and how surgical innovation is shaping the future of lung cancer treatment. Timestamps: 00:00 – Introduction 02:37 – Career beginnings 07:37 – Career highlights 11:38 – Thoracic oncology guidelines 15:26 – AI and big data 17:17 – Expanding lung cancer screening 19:29 – Robotic surgery 23:38 – Targeted therapies 27:23 – Cancer staging 30:44 – Lung volume reduction surgery 35:10 – Current trials 40:50 – Three wishes for healthcare

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

How ready are you to optimally manage subcutaneous immunotherapy in your practice? Credit available for this activity expires: 6/25/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002630?ecd=bdc_podcast_libsyn_mscpedu

In the wake of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® put together an X Spaces discussion hosted by Stephen Liu, MD, and Joshua Sabari, MD, to highlight the most intriguing and practice-changing lung cancer abstracts. Discussed topics ranged from long-term follow-up with commonplace therapies to an analysis of what time of day is the best to administer immunochemotherapy.  Liu, an associate professor of Medicine at Georgetown University, and the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Sabari, an assistant professor in the Department of Medicine at the NYU Grossman School of Medicine, and the director of High Reliability Organization Initiatives at the Perlmutter Cancer Center, shared expert insights on the latest non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) breakthroughs. Trials of note that they discussed included: The phase 3 DeLLphi-304 trial (NCT05740566) - Tarlatamab (Imdelltra) versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304.1 The phase 3 IMforte trial (NCT05091567) - Lurbinectedin (Zepzelca; lurbi) + atezolizumab (Tecentriq; atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial.2 The phase 3 CheckMate 816 trial (NCT02998528) - Overall survival with neoadjuvant nivolumab (Opdivo; NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.3 The phase 3 PACIFIC15 trial (NCT05549037) - Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non–small cell lung cancer.4 The phase 3 Beamion LUNG-1 trial (NCT04886804) - Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non–small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial.5 The phase 3 ARTEMIA trial (NCT06472245) - Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non–small cell lung cancer and secondary resistance to immunotherapy. References Rudin C, Mountzios G, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304. J Clin Oncol. 2025;43(suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008 Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006 Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab + chemotherapy in patients with resectable NSCLC in CheckMate 816. J Clin Oncol. 2025;43(suppl 17):LBA8000. doi:10.1200/JCO.2025.43.17_suppl.LBA8000 Zhang Y, Huang Z, Zeng L, et al. Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. J Clin Oncol. 2025;43(suppl 16):8516. doi:10.1200/JCO.2025.43.16_suppl.8516 Sabari JK, Nadal E, Hendriks L, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): results from the Beamion LUNG-1 trial. J Clin Oncol. 2025;43(suppl 16):8620. doi:10.1200/JCO.2025.43.16_suppl.8620 Liu SV, Guibert C, Tostivint EP, et al. Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy. J Clin Oncol. 2025;43(suppl 16):TPS8651. doi:10.1200/JCO.2025.43.16_suppl.TPS8651

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel's promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative. 00:00 Introduction and Guest Welcome00:59 Early Career and Passion for Medicine02:09 Transition to Industry and GSK Experience04:50 Building Successful Organizations07:42 Innovative Models in Pharma19:03 Joining Candel Therapeutics and Vision for the Future25:15 Transforming Cancer Treatment27:24 Challenges in Biotech Market28:45 Strategic Decisions and Prioritization31:39 Collaborations and External Partnerships33:07 Innovative Approaches and Future Prospects44:23 Leadership and Personal Insights Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Paul Peter Tak;LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate 816. They explore the implications of these findings for clinical practice, including the challenges of managing immune-related side effects and the potential for neoadjuvant immunotherapy to improve patient outcomes. The conversation also touches on the economics of oncology and the surprising results regarding the timing of immunotherapy administration.Studies discussed in the episode:Phase 3 DeLLphi-304NeoADAURACheckmate816IMFORTE studyRandomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.AND MORE!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

This episode featuring clinician-scientist and expert in liquid biopsy development, Dr. Lindsey Cotton, who explores the evolving science of lung cancer biomarkers and their role in early detection. Listen in to learn more about the current landscape, benefits and challenges of both organ-specific and multi-cancer tests. The highly informative discussion aims to clarify what these tests can and cannot tell us today, along with a forecast for tomorrow.

Early detection of lung cancer can save lives. In this essential episode, two-time survivor and LCFA co-founder David Sturges shares how screening helped him beat lung cancer—twice. Joined by Dr. Denise Aberle and LCFA-funded researcher Dr. Kellie Smith, this episode dives into why lung cancer is often diagnosed late, what new screening methods can do to change that, and what the future of early treatment might look like. Guests David Sturges, Lung Cancer Survivor & LCFA Co-founder  Dr. Denise Aberle, Thoracic Radiologist, UCLA Medical Center Kellie Smith, Ph.D., Assistant Professor of Oncology, Johns Hopkins University & LCFA Early Career Researcher Show Notes | Transcript  

This episode of 'Conversations in Lung Cancer Research' features Dr. Anna McLean, Dr Mark Adams, and Dr Sagun Parakh, discussing research on the microbiome and its influence on lung cancer treatment outcomes. They delve into the differences between the gut and lung microbiomes, methods for studying these microorganisms, and the potential for the microbiome to serve as biomarkers for treatment response and immune-related adverse events. They also cover the importance of collaboration and larger data sets in advancing this promising area of research.(00:00) Introduction(01:47) Understanding the Microbiome(03:40) Gut and Lung Microbiome Relationship(05:07) Challenges in Lung Microbiome Research(05:37) Microbiome's Role in Lung Cancer Risk(06:57) Techniques for Studying the Microbiome(10:33) Collaborative Efforts in Microbiome Research(16:09) Potential of Microbiome Modulation(20:35) Patient Advice and Future Directions(25:33) Conclusion and Final Thoughts

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC has reinstated around 460 employees who were previously fired, with the rehired staff working on viral disease prevention efforts and sexual health testing labs. This comes amid protests and shake-ups at the agency, including the overhaul of the vaccine advisory committee. Experts are concerned about newly appointed members, some of whom are known anti-vaxxers, potentially relitigating recommendations. Sen. Bill Cassidy is being urged to step up in response to these concerns.In other news, NuVation has received FDA approval for its oral lung cancer drug, Biontech has acquired CureVac in a $1.25 billion all-stock deal, and RFK Jr. has named new CDC vaccine advisors following a "clean sweep." Additionally, InVitro Cell Research is focused on discovering interventions to slow aging and prevent age-related diseases and is hiring scientists. The newsletter also includes information on layoffs at Genentech and Vertex.RFK Jr. has named eight new members to the CDC vaccine committee, replacing the 17 members he removed earlier in the week. The new choices seem to align with Kennedy's anti-vaccine views, causing concern among analysts. The HHS secretary's decision to appoint these scientists has raised questions about the committee's future direction.

In this second episode of our lung cancer miniseries, Jonathan Sackier is joined by David Baldwin, a leading expert in screening, epidemiology, and policy. Baldwin reflects on national screening programmes, groundbreaking trials, and how AI, big data, and evidence-based guidelines are reshaping lung cancer care. Timestamps: 00:00 – Introduction 03:17 – Key takeaways from the UKLS trial 11:10 – Boosting participation in screening studies 17:04 – The Targeted Lung Health Check programme 23:30 – Understanding large datasets in lung cancer epidemiology 32:44 – AI and big data in lung cancer imaging 41:43 – Shaping national guidelines 47:47 – Are we doing enough to prevent lung cancer? 53:06 – Baldwin's three wishes for healthcare

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with CTSNet JANS Editor Dr. Mateo Marin-Cuartas, a cardiac surgeon in the University Department of Cardiac Surgery at the Leipzig Heart Center, Germany, about surgical aortic valve replacement (SAVR) vs transcatheter aortic valve replacement (TAVR). Chapters 00:00 Intro 00:57 Dr. Marin-Cuartas Feature 02:28 SHURUI Robot Feasability 05:09 Touching as Diagnostic Test 09:06 Removal of Rib Stab Hardware 13:00 Resectable EGFR-Positive NSCLC 16:12 On-Pump Beating Heart MVR 17:56 Post-Infarction Myocardial Rupture 19:52 Head-First Graft Technique 22:18 SAVR vs TAVR, Dr. Marin-Cuartas 46:44 Upcoming Events 47:52 Closing They discuss SAVR and TAVR guidelines, the suitability of SAVR vs TAVR for patients aged 65-75, and mechanical heart valves. They also explore surgery after TAVR, TAVR after TAVR, and the future of addressing aortic valve stenosis.   Joel also highlights recent JANS articles on the safety and feasibility of novel single-port robotic-assisted lobectomy/segmentectomy for lung cancer, touching (proximity) as a companion diagnostic test, long-term outcomes after removal of rib stabilization hardware in patients with blunt chest trauma, and advancing the needle on the management of resectable EGFR-positive NSCLC.    In addition, Joel explores an on-pump beating heart mitral valve repair through right anterior minithoracotomy, post-infarction myocardial rupture treated with surgical repair and graded mechanical support, and a head-first graft technique in aortic arch replacement. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer  2.) Touching (Proximity) as a Companion Diagnostic Test   3.)  Long-Term Outcomes After Removal of Rib Stabilization Hardware in Patients With Blunt Chest Trauma  4.) Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?  CTSNET Content Mentioned  1.) On-Pump Beating Heart Mitral Valve Repair Through Right Anterior Mini Thoracotomy  2.) Drain, Patch, Unload: Post-Infarction Myocardial Rupture Treated With Surgical Repair and Graded Mechanical Support  3.) Head-First Graft Technique in Aortic Arch Replacement  Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

HOST: Hildy Grossman, CO-HOST: Jordan Rich GUESTS: Jaclyn LoPiccolo, MD, Ph.D., Pasi Janne, MD, Ph.D., Dana Farber Cancer Institute and Jill Feldman, EGFR Resisters Hildy opens with a powerful anecdote about an early Upstage Lung Cancer Board member whose mother, grandmother, and aunt all had lung cancer. She endured months of allergy and antibiotic treatments … Continue reading ALL IN THE FAMILY Is Lung Cancer Inherited? →

Drs. Scott and Liu discuss the safety of treatments for HER2-mutant lung cancer, including key toxicities, management strategies, and how prior therapies might affect treatment decisions.

Meet Tara Diehl and Dr. Katie Berlin and soak in hope and love as they discuss the inspiring story of Dunbar, Tara's 12-year-old dog diagnosed with primary undifferentiated pulmonary carcinoma. From the initial harrowing diagnosis to numerous treatments, including surgery, chemotherapy, and the promising effects of Palladia, Dunbar's story is a testament to hope, resilience, and the power of a dedicated dog mom … and dog insurance! The discussion highlights the importance of pet insurance, holistic care approaches, and the invaluable bond between pets, their owners, and veterinary teams. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Links: Dog Cancer Survival Guide - https://dogcancerbook.com/ Apocaps – https://apocaps.com/ Chapters: 00:00 Living in the Moment: Dunbar's Journey Begins 01:03 The Diagnosis: A Vet Tech's Worst Fear 03:18 Dunbar's Personality Shines Through 06:19 The Battle with Cancer: Treatment and Hope 08:52 Insurance and Financial Relief 14:04 A Comprehensive Approach: Supplements and Alternative Therapies 17:16 Dunbar's Resilience and Joy 18:09 Dog Cancer Resources and Support 18:38 The Impact of Attitude on Treatment 19:10 Dunbar's Medical Journey 23:57 Dunbar's Miraculous Recovery 25:26 Dunbar's Current Life and Activities 26:40 The Emotional Bond with Veterinary Teams 29:47 Final Thoughts and Encouragement 33:55 Closing Remarks and Resources   Get to know Dr. Katie Berlin: https://www.dogcancer.com/people/katie-berlin-dvm/ Get to know Tara Diehl: https://www.dogcancer.com/people/tara-diehl/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

BUFFALO, NY – June 9, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis.” In this study, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis and the Richard L. Roudebush Veterans Affairs Medical Center, researchers investigated how cigarette smoke and reduced DNA repair capacity contribute together to the development of lung cancer. They found that when a critical DNA repair protein called XPC is decreased and lung cells are exposed to cigarette smoke, the combination causes extensive damage and significantly increases cancer risk. Non-small cell lung cancer (NSCLC) develops through both genetic and environmental factors. This study focused on how cigarette smoke affects the body's natural ability to repair DNA. The researchers studied the role of XPC, a protein essential for recognizing and repairing harmful DNA changes caused by tobacco smoke. They found that low levels of XPC — commonly seen in lung cancer patients — made lung cells less capable of repairing DNA. This made the cells unstable and more likely to become cancerous. These changes were most pronounced in normal lung cells, suggesting that the earliest stages of disease occur before cancer is even detected. The findings support a “double hit” model, where both cigarette smoke and reduced DNA repair work together to drive cancer development. In laboratory experiments, normal lung cells with low XPC levels showed more damage and cell death after cigarette smoke exposure. By contrast, lung cancer cells were more resistant to smoke damage, even when XPC was low, indicating that critical changes had likely occurred earlier in the disease process. “Our study suggests that cigarette smoke exposure leads to decreased XPC mRNA expression, exacerbates total and oxidative DNA damage, hinders NER, and may contribute to lung cancer development.” The study also showed that DNA repair ability declined significantly in healthy cells after smoke exposure, but this effect was not seen in cancer cells. In addition, the researchers confirmed that XPC gene activity was lower in actual lung tumor tissue compared to nearby healthy lung tissue. This pattern was consistent across both adenocarcinoma and squamous cell carcinoma, the two main types of NSCLC. These results add to our understanding of how lung cancer begins at the molecular level. By showing how cigarette smoke and reduced DNA repair combine to create genetic instability, the research points toward new strategies for prevention. A better understanding of XPC's role could help identify high-risk individuals and inform future efforts to stop lung cancer before it begins. DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer. Join us as we dive into five key studies that could change clinical practice: 1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer. 2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes. 3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies. 4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates. 5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights! #OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast

A pretty shhhhtty death this week!Episode notes:Brooklyn Nine-Nine' Andre Braugher Died of Lung Cancer, His Publicist SaysMatthew Perry wrote in his memoir that ketamine, the drug that led to his death, had his 'name written all over it'Rudy Giuliani is ordered to pay over $148 million to 2 Georgia election workers for defamationChinese mourners use AI to digitally resurrect the deadMarine Biologists Recently Spotted A Dolphin With Human-Like ‘Thumbs'

Stephen V. Liu, MD and Susan C. Scott, MD discuss advances in treating HER2-mutant lung cancer. Until recently, treatments for HER2-mutant lung cancer primarily involved chemotherapy, immunotherapy, and HER2-targeted therapies, with mixed results. Now, the treatment landscape of HER2-mutant lung cancer is changing.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning recaps the 33rd European Society of Thoracic Surgeons (ESTS) annual meeting in Budapest. Chapters 00:00 Intro 01:30 ESTS 2025 Conference 09:11 SHURUI Robot Study 10:04 Willard A. Fry 12:44 Transplant Recipient Pregnancy Outcomes 15:25 Low-Flow, Low-Gradient Aortic Stenosis 17:12 Warm Ischemic Intervals Effect 19:16 Extracorp Circulation vs Conventional 23:23 Femoral Cannulation for CPB Min Invasive 24:25 Valve Sparing Aortic Root Replacement 25:27 Valve Surgery Podcast w Michael Mack 27:21 Upcoming Events 27:54 Closing He discusses the key themes and takeaways from the event, the SHURUI single-port robotic system, the hands-on experience with the da Vinci Single-Port system led by Dr. Tom Routledge, and the extraordinary guest lecture from Ernő Rubik, the inventor of the Rubik's cube. Joel also highlights various presentations from the meeting, including “Does the Fissureless Technique Really Reduce Air Leak? Results of the Prospective Randomized Study Fissureless Versus Fissurefirst (3F Trial)” by Tom Routledge, “Tour D'Horizon About Potential Newcomings in the 10th Edition” by Valerie Rusch, and much more. Additionally, he pays tribute to Willard A. Fry and his significant accomplishments.   Joel also highlights recent JANS articles on pregnancy outcomes in 53 female lung transplant recipients, outcomes of surgical versus transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis, the effect of warm ischemic intervals on primary graft dysfunction in normothermic regional perfusion for donation after circulatory death heart transplant, and minimal invasive extracorporeal circulation versus conventional cardiopulmonary bypass in cardiac surgery.  In addition, Joel explores femoral cannulation for CPB during minimally invasive cardiac surgery, a presentation from the Society for Cardiothoracic Surgery in Great Britain and Ireland annual meeting on “Valve Sparing Aortic Root Replacement—Tips and Tricks,” and the one-year anniversary episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with cardiothoracic surgery pioneer Dr. Michael Mack on the future of valve surgery. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Pregnancy Outcomes in 53 Female Lung Transplant Recipients  2.) Outcomes of Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis  3.) The Effect of Warm Ischemic Intervals on Primary Graft Dysfunction in Normothermic Regional Perfusion for Donation After Circulatory Death Heart Transplant  4.) Minimal Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery: A Contemporary Systematic Review and Meta-Analysis  CTSNET Content Mentioned  1.) Femoral Cannulation for CPB During Minimally Invasive Cardiac Surgery  2.) SCTS 2025 | Valve Sparing Aortic Root Replacement—Tips and Tricks  3.) The Atrium: The Future of Valve Surgery  Other Items Mentioned  1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer  2.) A Eulogy for Willard A. Fry  3.) 2025 SCTS Annual Meeting Videos   4.) The Atrium—All Episodes   5.) Career Center   6.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche and Jazz Pharmaceuticals presented data at ASCO showing that their drug combination improved survival in a phase III lung cancer trial, with analysts noting a strong treatment effect. Jazz has filed for FDA approval for the combination, which could provide an alternative to monotherapy treatments from Roche and AstraZeneca. Trump's tariffs could potentially endanger the rare disease space, according to industry experts. Other news includes Kymera's success with a protein degrader candidate, Amgen's IMDelltra boosting survival in small cell lung cancer, and concerns about the impact of FDA guidelines on nitrosamine testing. BioAgilytix will be at BIO International to discuss their drug production capabilities. Other news includes Kura's new data in acute myeloid leukemia, Keros' layoffs, Regeneron's investment in a Chinese obesity drug, and Sanofi's acquisition of Blueprint to expand their rare disease portfolio. Upcoming events include webinars on AI in life science R&D and the crisis facing the pharma industry. Job opportunities in clinical data management, regulatory affairs, and scientific roles are also highlighted.

Imagine being told you only have 12 months to live. What would you do with your time? Today on Your Money, Your Wealth podcast number 532, Big Al Clopine, CPA and Executive Producer Andi Last are thrilled to welcome Jonathan Clements back for his fourth appearance. For thirty years, Jonathan has been known for his personal finance writing: in his column “Getting Going,” which appeared in the Wall Street Journal over 1,000 times starting in 1994, on his website HumbleDollar.com, and in his many acclaimed books. About a year ago, Jonathan Clements was diagnosed with a rare form of lung cancer and was told he had about a year to live. Today we're celebrating the fact that he is still here with us, and we're inspired by his decision to use his precious time to launch The Jonathan Clements Getting Going on Savings Initiative. Watch or listen to find out how you can get a free Kindle copy of Jonathan's new book, and how you can help Jonathan pay it forward for the next generation. Free financial resources & episode transcript: https://bit.ly/ymyw-532 The first 100 people to email us will receive a free Kindle copy of The Best of Jonathan Clements: Classic Columns on Money and Life WATCH Retirement Sabotage! 12 Post-Retirement Money Mistakes to Avoid on YMYW TV ASK Joe & Big Al for your Retirement Spitball Analysis SCHEDULE your Free Financial Assessment SUBSCRIBE to YMYW on YouTube DOWNLOAD more free guides READ financial blogs WATCH educational videos SUBSCRIBE to the YMYW Newsletter Timestamps:  00:00 - Intro: This Week on the YMYW Podcast 02:53 - Jonathan Clements' Getting Going on Savings Initiative 05:23 - $1,000 Roth IRA Contributions and Personal Finance Education for Young Adults 07:55 - Exponential Growth: The Sooner You Save, The Better 09:44 - Research Study Will Measure Impact on Young Savers 11:56 - Financial Education is Important 14:05 - The John C. Bogle Center for Financial Literacy 14:38 - The First 100 People to Email Us Receive a Free Copy of The Best of Jonathan Clements: Classic Columns on Money and Life 15:45 - How Does a Healthy 62-Year-Old Non-Smoker End Up Living With Stage IV Lung Cancer? The EGFR Exon 20 Insertion Mutation 18:52 - HumbleDollar.com, The Jonathan Clements Getting Going on Savings Initiative, and The Best of Jonathan Clements Book

Shining a light on the caregiving journey for lung cancer patients, Dr. Allison Applebaum, founder of the Caregiver's Clinic at Memorial Sloan Kettering Cancer Center, and caregiver Gail Fackler, along with her husband, Jim, speak candidly about the mental health challenges caregivers face, including anxiety, depression, and PTSD. The conversation covers the overwhelming realities of caregiving, from managing medical decisions to coping with guilt and loss of identity. Gail and Jim share raw, honest stories about how caregiving has transformed their lives and relationships. Practical strategies for caregivers—such as task management, setting boundaries, and finding support networks—offer hope and guidance. Learn more about the  critical importance of mental health support for caregivers and the power of community in navigating this journey. Guests Dr. Allison Applebaum, Founding Director, Caregiver's Clinic, Memorial Sloan Kettering Cancer Center Gail and Jim Fackler, Lung Cancer Caregivers and Patient   Show Notes | Transcript | Watch Video

In this episode, Jonathan Sackier kicks off a special miniseries on lung cancer with Haval Balata, Consultant Respiratory Physician at Manchester University NHS Foundation Trust. From the Manchester Lung Health Check to robotic bronchoscopy, Balata shares insights into pioneering early detection efforts, the challenge of public misconceptions, and innovations reshaping lung cancer screening and diagnosis. Timestamps: 03:12 – Inspiration to specialise 04:09 – Early diagnosis barriers 08:02 – Manchester Lung Health Check 14:10 – Robot-assisted bronchoscopy 19:24 – Public misconceptions 28:57 – Risk stratification & follow-up 34:24 – Innovations in early detection 37:10 – Hopes for the future 41:22 – Three healthcare wishes

In this deeply inspiring follow-up conversation, Jay Jay shares the life-changing role that cannabis has played in her journey, including her unexpected recovery from severe pain, a recurrence of brain tumors, and even a broken vertebrae from a seizure. She also speaks candidly about addiction, emotional healing, diet changes, and the power of education. Now working as Executive Director of EduCanNation, Jay Jay is paying it forward by helping others navigate their healing paths with cannabis and community.00:37 – Introduction: Jay Jay's return, 5+ years post-terminal diagnosis01:22 – Jay Jay's gratitude for the podcast and tribute to Corrie Yelland02:30 – Physical vs. emotional healing, addiction, and cannabis support03:44 – 10 months of undiagnosed pain before Jay Jay insisted it was cancer05:04 – Emotional toll of her prognosis and the loss of her mother06:11 – A fight for her life begins—rejection of the medical “death sentence”07:05 – No chemo, no radiation offered—turning to cannabis07:27 – The moment of clarity: watching Weed the People07:59 – Early cannabis oil experience: rookie mistake, fast pain relief09:20 – Daily dose now: 1.5 to 2 grams; feeling better than ever10:00 – A gene mutation leads to targeted therapy11:29 – Brain metastases return in 2023—11 tumors, then 8 more12:37 – Seizure leads to spinal fracture; cannabis helps her heal13:56 – Headaches and midline shift caused by brain tumors15:22 – Ian shares cannabis success stories for brain cancer15:58 – Jay Jay on life transformation—body, mind, and soul16:18 – Gaining new perspective after a “death sentence”17:07 – Her advice to those newly diagnosed: don't lose hope18:38 – The birth of EduCanNation and its founding story20:16 – Jay Jay's cannabis education journey and certifications21:11 – Cannabis skepticism vs. chemo acceptance—societal brainwashing22:39 – Helping others: a story about supporting her father-in-law24:25 – Emotional resilience and growth24:41 – Diet transformation—from vegetarian to carnivore27:07 – Honouring individual needs: no one-size-fits-all diet28:03 – Feeling healthier than ever despite diagnosis28:10 – How to contact Jay Jay and connect with EduCanNation Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

LCC in Korean: Lung Cancer Updates & Future Directions by IASLC

In this episode, Dr. Paul Wheatley-Price chats with Dr. Dugald Seely, ND on naturopathic medicine and lung cancer - what is naturopathy vs alternative vs homeopathic medicine, how it can play a role within lung cancer care, the innovative research he's been doing, and busting some of the myths about CAM. Dr. Seely is a Naturopathic Doctor in Ottawa, CEO of the Center for Health Innovation, and Executive Director at the Patterson Institute for Integrative Oncology Research at the Canadian College of Naturopathic Medicine.

Today, Paul reflects on the work of Jonathan Clements, an author and former writer for The Wall Street Journal, who has not stopped trying to leave a legacy amid a terminal cancer diagnosis. Listen along as Paul explains why it is so important to have voices like these in the investing world and why the concept of market efficiency is the foundation that you build many other investing concepts on top of.   For more information about what we do or how we can help you, schedule a 15-minute call with us here: paulwinkler.com/call. 

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

- Understanding Precision Medicine: Overview & Value of Precision Medicine - How Precision Medicine is Different from Targeted Treatments? - Precision Medicine's Role in Informing Treatment Decisions: Predicting Response to Treatment - The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer - Talking with Your Health Care Team About Precision Medicine & its Benefits - The Role of the Pathologist - OpenNotes – Asking Your Health Care Team & Pathologist to Help You Understand OpenNotes - How Precision Medicine Contributes to Treatment Options & Quality of Life - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology & Prepared List of Questions - Questions for Our Panel of Experts

Updated For 2025! This Week In Wrestling History (Season 3 Week 20) covering the period of 5/14 thru 5/20. Running Time: 4 Hours 10 Minutes. This Week In Wrestling History hosted by Don Tony first aired in 2018 and spanned two seasons. After much demand, these retro episodes return REMASTERED and UPDATED FOR 2025. Wrestling history up to and including 2024 has been added! Hundreds of hours of original wrestling clips & stories. Enjoy this deep dive into pro wrestling's awesome history. RUNNING TIME: 4 Hours 10 MinutesHosted by Don Tony SYNOPSIS: S3 E20 (05/14 - 05/20) The era of Bruno begins: Bruno Sammartino def Buddy Rogers to win WWWF Championship. Andy Kaufman passes away from Lung Cancer at 35 years old. Audio: AWA fu**ery: Playboy Buddy Rose & Doug Somers win the AWA Tag Team titles on a count out (from Scott Hall and Curt Hennig). Looking back at WCW Capital Combat: The Return Of Robocop (1990). Looking back at WCW SuperBrawl (1991). Audio: Sid Vicious vs El Gigante: Stretcher Match Looking back at WCW WarGames (1992). Papa Shango places a voodoo curse on a vomiting Ultimate Warrior, and the feud begins. AAA Promotion makes its debut (1992). Audio: The biggest upset in Raw histoy? The Kid def Razor Ramon. Audio: Marty Janetty makes WWF return and def Shawn Michaels for IC Championship. 'A Current Affair' episode debuts profiling the tragedies surrounding the Von Erich family. Looking back at ECW: When Worlds Collide (1994). Audio: Arn Anderson speaks on his one match in ECW and why it sucked. Looking back at AAA Triplemania II-B event (1994). WWF makes significant changes in drug policy in an attempt to prevent abuse. Looking back at the first ever WWF In Your House PPV (1995). Audio: Bob Backlund announces his candidacy for President and makes some comical errors at some historical events. Infamous Cliq Curtain Call takes place at Madison Square Garden. Audio: Triple H, Jim Cornette, Scott Hall, and Kevin Nash speak on the infamous MSG Curtain Call. Looking back at WCW Slamboree (1996, 1997, 1998). HBK infamous 'Sunny Days' Promo on Bret Hart airs on Raw. Audio: Sean Waltman reveals a 'Sunny Day' story involving Shawn Michaels. People Magazine wasn't the only fools running high profile Internet Polls in 1998. Looking back when Ric Flair had led Time Magazine's 'Person Of The Century' Poll. Looking back at ECW 'It Ain't Seinfeld' event (1998). Taz debuts the FTW (F*** The World) Championship. Audio: Eric Bischoff taunts Vince McMahon on WCW Thunder. Audio: Chris Jericho's introduces the participants in the Cruiserweight Battle Royal at Slamboree 1998. Audio: The night Dean Malenko received one of the loudest pops in WCW history. Referee Charles Robinson suffers collapsed lung after taking an elbow drop by Macho Man Randy Savage. Looking back at WCW No Mercy UK PPV (1999). Looking back at ECW Hardcore Heaven PPV (1999, 2000). Audio: Godfather's Ho (Bobcat) wins WWF Hardcore Title from Crash Holly. Audio: Don Tony's favorite WWF Hardcore Title match: Gerald Brisco vs Crash Holly. Looking back at WWE Judgement Day PPV (2000, 2001, 2002, 2003, 2004, 2007, 2008, 2009). Vince McMahon makes return appearance on HBO's 'On The Record with Bob Costas'. Zach Gowan makes WWF TV debut - by having his prosthetic leg yanked off by Rowdy Roddy Piper. Ron 'The Truth' Killings wins NWA World Heavyweight Championship for the 2nd time. Mordecai makes WWE main roster debut. Audio: Bobby Heenan on The Dennis Miller Show. TNA suspends Jeff Hardy. Looking back at TNA Hard Justice PPV (2005). Tickets for ECW One Night Stand go on sale and immediately sells out. Looking back at TNA Sacrifice PPV (2006, 2010). 'See No Evil' starring Kane hits movie theatres. WWE releases Sabu, Shelly Martinez, Scotty 2 Hotty, Nick Mitchell, Carlito and Angel Williams (Angelina Love). Audio: Bret Hart defeats The Miz to win the WWE US Championship. Hulk Hogan sues Fruity Pebbles Cereal (Post). Audio: TNA rebrands as 'Impact Wrestling' and 'Wrestling Matters'. TNA signs Brooke Hogan. Looking back at WWE Over The Limit PPV (2012). Looking back at WWE Extreme Rules PPV (2013). Audio: Kevin Owens makes WWE main roster debut. Looking back at NXT TakeOver: Unstoppable (2015). Samoa Joe makes NXT debut. Looking back at WWE Payback PPV (2015). Destination American announces cancellation of TNA Programming effective September 2015. Audio: New Day 'Time Machine' skit poking fun at The Vaudvillains Looking back at NXT TakeOver: Chicago (2017) WWE signs Io Sky (Io Shirai) WWE and FOX agree on a five-year deal to air SmackDown on Fox beginning in 2019 Charges dropped in the sexual assault case against Enzo Amore Ashley Massaro tragically passes away at 39 Audio: Mick Foley introduces WWE 24/7 Championship on RAW to a less than stellar response from live audience and IWC Looking back at WWE Money In The Bank 2019 Audio: Brock Lesnar makes surprise return, screws Mustafa Ali and wins MITB Briefcase Audio: Mustafa Ali reveals how everything went down behind the scenes at MITB and Brock Lesnar return Audio: Firefly Fun House takes a very dark turn as Bray Wyatt introduces us to The Fiend Audio: Shad Gaspard tragically passes away at 39 (news coverage) D-Von Dudley retires from in-ring competition Audio: Jim Cornette stirs up controversy discussing Becky Lynch pregnancy Looking back at WWE Backlash 2021 Looking back at Impact Wrestling: Under Siege 2021 Alexander Wolfe is kicked out of Imperium AND WWE in the same week WWE releases eight including Velveteen Dream, Alexander Wolfe, Jessamyn Duke, Adnan Virk and Drake Wuertz WBD announces new AEW: Rampage TV series coming to TNT   Sasha Banks and Naomi quit WWE Audio: Michael Cole on air reaction to Sasha Banks and Naomi quitting WWE Stephanie McMahon announces an abrupt leave of absence from WWE Audio: RK-Bro (RAW Tag Champions) vs The Usos (SmackDown Tag Champions) battle in a Tag Team Unification Match Audio: Max Dupri makes his WWE TV debut WBD announces new AEW: Collision TV series coming to TNT   AEW announces the creation of a new YouTube series: "Meal And A Match" Ruby Soho and Angelo Parker get married Mark Henry leaves AEW  Audio: The beginning of the end of Ricky Starks in AEW. Ricky Starks expresses frustration over not being used and media pushing injuries as the excuse  And so much more! RIGHT CLICK AND SAVE to download the AUDIO episode of THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) CLICK HERE to listen to COMMERCIAL FREE (PATREON) episode of THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) CLICK HERE to listen to THIS WEEK IN WRESTLING HISTORY S3 E20 (5/14 – 5/20) online CLICK HERE to access previous episodes for all the shows ==== CELEBRATE 20 YEARS OF DON TONY AND KEVIN CASTLE WITH THE DTKC 20 YEAR ANNIVERSARY SHIRT! CLICK HERE for DTKC Pro Wrestling Tees Store ==== Want to help promote our shows and get a special shout-out on the next show? Stop by Apple Podcasts (CLICK HERE) or SPOTIFY (CLICK HERE) and leave a review! Join Don Tony And Kevin Castle Show Patreon Family, and get a special shout-out on the next show! CLICK HERE ==== DON TONY AND KEVIN CASTLE *PATREON* AND *YOUTUBE CHANNEL MEMBERSHIPS: You can send additional support for Don Tony And Kevin Castle and help grow and keep the brand alive, by becoming a member of DT/KC PATREON and/or YOUTUBE CHANNEL MEMBERSHIP FAMILY. Don Tony and Kevin Castle's PATREON has been around for over seven years! You can access all eight years of BONUS CONTENT right now including: Ad-Free episodes of all of the weekly Non-Patreon shows Retro episodes of The Don Tony And Kevin Castle Show going back as early as 2004 (Retro Episodes added each week!) Weekly Patreon podcasts hosted by Don Tony Kevin Castle's entire library of Patreon exclusive shows. 2000+ hours of Patreon exclusive shows never released publicly! (Over 8 Years of Patreon Exclusive Content!) CLICK HERE to access DT/KC Patreon now! YOUTUBE CHANNEL MEMBERSHIPS: Another option is to become a CHANNEL MEMBER on YouTube. Get exclusive enhanced versions of weekly shows, access to DT's weekly Patreon show, retro DTKC Show episodes, giveaways and more. CLICK HERE for more details and to join The DT/KC YouTube Channel Member Family! ==== CHECK OUT OUR CONTENT ACROSS THESE PLATFORMS: CLICK HERE FOR APPLE PODCASTS CLICK HERE FOR SPOTIFY CLICK HERE FOR ANDROID CLICK HERE FOR AMAZON MUSIC CLICK HERE FOR GOOGLE PODCASTS CLICK HERE FOR PANDORA CLICK HERE FOR PODBEAN CLICK HERE FOR IHEARTRADIO CLICK HERE FOR DON TONY AND KEVIN CASTLE SHOW MERCHANDISE! ==== WEEKLY SHOW SCHEDULE (UPDATED: JANUARY 2025): WWE RAW RECAP AND WRESTLING NEWS REPORT: LIVE EVERY MONDAY NIGHT at 10:45PM ET after WWE RAW on DTKCDiscord.com DT VIPATREON: Patreon Exclusive Show hosted by Don Tony LIVE EVERY TUESDAY at 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every WEDNESDAY morning at DonTony.com (and across all audio platforms) THIS WEEK IN WRESTLING HISTORY: Posted every THURSDAY at DonTony.com (and across all audio platforms) CASTLE/KNT CHRONICLES: Patreon Exclusive Show hosted by Kevin Castle and Trez LIVE EVERY THURSDAY 8:30PM on DTKC Patreon Channel (https://www.patreon.com/dontony) PRO WRESTLING NEWS UPDATES: Posted every FRIDAY morning at DonTony.com (and across all audio platforms) PRO WRESTLING WEEKEND NEWS UPDATE: Posted every SATURDAY at DonTony.com (and across all audio platforms) THE SIT-DOWN w/DON TONY: VIDEO PODCAST hosted by Don Tony LIVE EVERY SUNDAY at 8PM on YouTube (www.YouTube.com/DonTony) WWE/AEW PPV RECAP/REVIEW: (Posted MONDAY NIGHT as part of Don Tony and Kevin Castle Show) ==== SOCIAL MEDIA / WEBSITE / CONTACT INFO: Twitter: https://twitter.com/dontonyd Patreon: https://www.patreon.com/dontony Facebook: https://facebook.com/DTKCShow YouTube: https://www.youtube.com/dontony Website: https://www.wrestling-news.com

Is sugar carcinogenic?!

The latest podcast episode of Veteran Oversight Now highlights the VA OIG's oversight work during April 2025, including three healthcare facility inspections reports on facilities in Tennessee, New York, and Colorado.   April 2025 Monthly HighlightsEach month, the VA Office of Inspector General publishes highlights of our congressional testimony, investigative work, and oversight reports. In April 2025, the VA OIG published 12 reports that included 51 recommendations. Report topics varied from a review to determine whether claims processors are properly assigning effective dates for PACT Act-related claims to an inspection related to a patient's delayed diagnosis and treatment for lung cancer at the VA Eastern Kansas Healthcare System in Topeka and Leavenworth.  VA OIG investigative efforts helped resolved allegations that a drug and alcohol rehabilitation facility, Seabrook House in New Jersey, submitted claims to VA's Community Care program and the state's Medicaid program for short-term residential treatment and partial hospitalization care for which it was not properly licensed or contracted and misled state inspectors. In a civil settlement, Seabrook agreed to pay $19.75 million to resolve False Claims Act allegations. Of this amount, VA will receive $19.15 million.  Meanwhile, 12 employees of the Louis Stokes Cleveland VA Medical Center pleaded guilty to theft after receiving more than $396,000 in Pandemic Unemployment Assistance benefits by falsifying their applications and failing to disclose their employment and wages earned at VA, and a physician at the Bedford VA Medical Center in Massachusetts was arrested and charged in the District of Massachusetts with the receipt and possession of child pornography.Read the full monthly highlights.   Related Reports:The PACT Act Has Complicated Determining When Veterans' Benefits Payments Should Take EffectDelayed Diagnosis and Treatment for a Patient's Lung Cancer and Deficiencies in the Lung Cancer Screening Program at the VA Eastern Kansas Healthcare System in Topeka and LeavenworthHiring of Claims Processors Generally Met Requirements and the Attrition Rate Remained Steady

See if you can follow along and recall this underrated comic book adaptation as well as Michael did!

Mikayla Pittman, Manager of Nationwide Lung Cancer Screening for the American Lung Association, joins Lisa Dent to discuss the rise of lung cancer in those who have never smoked.

Program notes:0:47 Gun injuries and deer hunting season1:47 Other associated injuries2:47 Coincidence of hunting?3:48 Restrict hunting guns to that use4:10 Can we avoid surgery in some with cancer?5:10 Dostarlimab treatment6:10 Can help avoid surgery in few who have this mutation7:10 Look at specific pathways7:30 Lung cancer treatment8:32 71% responded9:12 Impact of Pepfar funding freeze10:12 Looked at waiver scenarios11:12 Decreased deaths and infection12:13 Takes time to resume13:06 End

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

Arthur Robin Williams is an associate professor of clinical psychiatry at Columbia University and a research scientist at the New York State Psychiatric Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.R. Williams. Death and Taxes — Is Alcohol the Solution? N Engl J Med 2025;392:1665-1667.

In this episode, you'll hear about the latest developments in tailoring cancer treatments to individual patients using Precision Oncology.  Two thought leaders, Simone Ndujiuba, a Clinical Oncology Pharmacist at Prime Therapeutics, and Karan Cushman, Head of Brand Experience and host of The Precision Medicine Podcast for Trapelo Health, discuss real-world research that is paving the way for Prime and our partners to help providers reduce turnaround times so patients can start treatment as soon as possible.  Join your host Maryam Tabatabai as they dig into this evolving topic of precision oncology. www.primetherapeuitics.com ⁠Chapters⁠Defining precision medicine (08:50)Evaluating real-world operational process of biomarker testing (14:36)Turnaround times are crucial (17:40)A patients view into the importance of time (24:39)Technology and process aid in time and process (29:30)Helping bridge knowledge gaps for providers and payers (33:55) The focus is on Precision Oncology right now (37:00)Precision medicine in other disease categories (40:09)Future of precision oncology is bright (42:07) References Singh, B.P., et al. (2019). Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). American Society of Clinical Oncology. https://meetings. asco.org/abstracts-presentations/173392 Evangelist, M.C., et al. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41(Supplement 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.9109. Ossowski, S., et al. (2022). Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small cell lung cancer. Journal of Clinical Oncology, 18(11). https://doi.org/10.1200/OP.22.00260 Naithani N, Atal AT, Tilak TVSVGK, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021 Jul;77(3):258-265. doi: 10.1016/j.mjafi.2021.06.020.  Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019 Jul;24(7):e432-e440. doi: 10.1634/theoncologist.2019-0054.  MedlinePlus. What is genetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/genetics/understanding/testing/genetictesting/. MedlinePlus. What is pharmacogenetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetics%20(also%20called%20pharmacogenomics)%20is,your%20height%20and%20eye%20color.  Riely GJ, Wood DE, Aisner DL, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: non-small cell lung cancer, V3.2005. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.  Benson AB, Venook AP, Adam M, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: colon cancer, V3.2025. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Rosenberg PS, Miranda-Filho A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw Open. 2024 Jun 3;7(6):e2415731. doi: 10.1001/jamanetworkopen.2024.15731. PMID: 38857048; PMCID: PMC11165384. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002.The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice.

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications

Welcome back to this week's Friday Review where I can't wait to share with you the best of the week!     I'm looking forward to reviewing:     Puriya Skin Repair Foot Balm (product review) The Healthiest Toothpastes (product review) Lung Cancer & RX (research) Accurate Blood Pressure Reading (research)   For all the details tune into this week's Cabral Concept 3346 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3346 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!